First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trialAiping Zhou, Xinan Sheng, Xiubao Ren et al.|The Lancet Oncology|2025Cited by 10
Risk analysis of enfortumab vedotin: A real-world approach based on the FAERS databaseFu‐Chun Zheng, Yuanzhuo Du, Yuyang Yuan et al.|Heliyon|2024Cited by 3
The enigmatic interplay of immune cells and abnormal spermatozoa through Mendelian randomizationFu‐Chun Zheng, Bin Fu, Sheng Li et al.|American Journal of Reproductive Immunology|2024Cited by 2